glp 1 agonist dementia GLP-1 receptor agonists show promise in treating substance use disorders Glucagon-like peptide-1 (GLP-1) receptor agonists

Graphical abstract Table 1

The observational study looked at over 200,000 mammograms of women between the ages of 45 and 80 to assess breast cancer detection

The results of a trial of semaglutide in obese patients with HFpEF showed a significant amelioration of symptoms and improvements in motor function and weight loss compared with patients treated with a placebo

R.RossingP.MahaffeyK

5.2 Safety evaluation In both clinical trials and real-world settings, tirzepatide has demonstrated a favorable safety and tolerability profile

The berberine and semaglutide combination has gained attention as a way to enhance GLP-1 effects naturally